In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method

被引:48
作者
Singh, J
Rimek, D
Kappe, R
机构
[1] Helios Med Ctr, Haema Inst Lab Med, Dept Microbiol & Infect Dis, Erfurt, Germany
[2] Univ Hosp, Dept Med Microbiol, Rostock, Germany
[3] Univ Hosp, Hosp Hyg, Rostock, Germany
关键词
zygomycetes; susceptibility testing; microdilution;
D O I
10.1111/j.1439-0507.2005.01132.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The in vitro susceptibility of 15 strains of six genera of zygomycetes including Rhizopus oryzae (Rhizopus arrhizus), Rhizopus stolonifer, Mucor circinelloides (three), Absidia corymbifera (three), Rhizomucor pusillus (three), Cunninghamella bertholletiae (two), and Syncephalastrum racemosum (two) to nine antifungal agents were determined by the NCCLS M38-A broth microdilution method. Geometric means of the minimal inhibitory concentrations (MIC) were: amphotericin B 0.07 mg l(-1) (range 0.03-0.5 mg l(-1)), nystatin 0.83 mg l(-1) (range 0.25-4 mg l(-1)), itraconazole 0.59 mg l(-1) (range 0.03 to > 8 mg l(-1)), voriconazole 6.50 mg l(-1) (range 2 to > 8 mg l(-1)), ciclopiroxolamine 1.59 mg l(-1) (range 0.5-4 mg l(-1)), and amorolfine 9.19 mg l(-1) (range 1 to > 16 mg l(-1)). All strains were resistant to 5-flucytosine, fluconazole (MIC > 64 mg l(-1)) and caspofungin (MIC > 16 mg l(-1)).
引用
收藏
页码:246 / 250
页数:5
相关论文
共 21 条
[1]   BURN STRESS PSEUDODIABETES [J].
ARNEY, GK ;
PEARSON, E ;
SUTHERLAND, AB .
ANNALS OF SURGERY, 1960, 152 (01) :77-90
[2]   Quality control limits for broth microdilution susceptibility tests of ten antifungal agents [J].
Barry, AL ;
Pfaller, MA ;
Brown, SD ;
Espinel-Ingroff, A ;
Ghannoum, MA ;
Knapp, C ;
Rennie, RP ;
Rex, JH ;
Rinaldi, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3457-3459
[3]   Primary cutaneous Absidia corymbifera infection in a premature newborn [J].
Buchta, V ;
Kalous, P ;
Otcenásek, M ;
Vánová, M .
INFECTION, 2003, 31 (01) :57-59
[4]   In vitro susceptibilities of Zygomycota to polyenes [J].
Dannaoui, E ;
Meis, JFGM ;
Mouton, JW ;
Verweij, PE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (05) :741-744
[5]   Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis [J].
Dannaoui, E ;
Mouton, JW ;
Meis, JFGM ;
Verweij, PE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1953-1959
[6]   In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].
Dannaoui, E ;
Meletiadis, J ;
Mouton, JW ;
Meis, JFGM ;
Verweij, PE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52
[7]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[8]   Preface - Fungal infections, - Part I - Recent advances in diagnosis, treatment, and prevention of opportunistic mycoses [J].
Walsh, TJ ;
Rex, JH .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (04) :IX-X
[9]   In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi [J].
Johnson, EM ;
Szekely, A ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :741-745
[10]   MORPHOLOGICAL EFFECTS OF LIPOPEPTIDES AGAINST ASPERGILLUS-FUMIGATUS CORRELATE WITH ACTIVITIES AGAINST (1,3)-BETA-D-GLUCAN SYNTHASE [J].
KURTZ, MB ;
HEATH, IB ;
MARRINAN, J ;
DREIKORN, S ;
ONISHI, J ;
DOUGLAS, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1480-1489